Carl Zeiss Meditec AG (AFXG.DE)

Carl Zeiss Meditec AG (AFXG.DE) Trading on MT5 at XM

At XM we offer Carl Zeiss Meditec AG (AFXG.DE) stocks as cash CFDs. Our cash CFDs stocks are undated transactions that aim to replicate the cash price of the underlying stock, and so they are adjusted for any relevant corporate actions.

Open a Demo Account
Open an Account

Risk warning: FX and CFD trading involves a high risk of loss.

About Carl Zeiss Meditec AG (AFXG.DE) Trading

Founded in 2002 and headquartered in Jena, Germany, Carl Zeiss Meditec AG is an international medical technology company and the parent company of Carl Zeiss Meditec Group. Carl Zeiss Meditec AG manufactures high-tech medical lasers, ophthalmic diagnostic equipment, surgical microscopes and radiation therapy equipment. The company stock AFXG.DE is traded on the Frankfurt Stock Exchange.

Trading Conditions

Margin requirement 10 %
Spreads as low as 0.4
Symbols CarlZeiss
Description CarlZeiss
Min. Price Fluctuation 0.01000
Value of Minimum Price Fluctuation EUR 0.1
Value of 1 lot 10 Shares
Min/Max Trade Size 0.6/51
Swap Value in Margin Currency Long -2.44 %
Swap Value in Margin Currency Short -3.56 %
Limit and Stop Levels** 0.05
Total Volume Limit (per client)*** 383
Weekday 10:10-14:00,14:03-18:25 (GMT +2)
Monday Open 10:10 (GMT +2)   │   Friday Close 18:25 (GMT +2)
** Min. level for placing pending orders at a current market price.

*** Note that the maximum trading volume for CarlZeiss per client is 383 lots. This limit will be reviewed on a daily basis and updated according to the value of the instrument.

How to Start Trading Carl Zeiss Meditec AG (AFXG.DE)?

Step 1

Open an XM Real Account

Step 2

Download and login to the MT5 platform

Step 3

Double-click on Carl Zeiss Meditec AG (AFXG.DE) from the “Market Watch” to open an order for this instrument.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.